U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C12H15F2NO2.ClH
Molecular Weight 279.711
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MANIFAXINE HYDROCHLORIDE

SMILES

Cl.C[C@@H]1CO[C@](O)([C@H](C)N1)C2=CC(F)=CC(F)=C2

InChI

InChIKey=TWDNQLAJZYOSNV-FZHAGLAKSA-N
InChI=1S/C12H15F2NO2.ClH/c1-7-6-17-12(16,8(2)15-7)9-3-10(13)5-11(14)4-9;/h3-5,7-8,15-16H,6H2,1-2H3;1H/t7-,8+,12-;/m1./s1

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C12H15F2NO2
Molecular Weight 243.2498
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Manifaxine (GW 320659) is a highly selective neuronal norepinephrine and dopamine re-uptake inhibitor. It has been in phase II clinical trials by GlaxoSmithKline for the treatment of attention deficit hyperactivity disorder and obesity. Manifaxine development has been discontinued.

CNS Activity

Originator

Approval Year

PubMed

Sample Use Guides

In Vivo Use Guide
a multicenter, open-label, dose-titration study of seven daily dose levels of manifaxine (GW 320659): 1.25, 2.5, 5, 7.5,10,12.5, and 15 mg.
Route of Administration: Unknown
Substance Class Chemical
Record UNII
7ULY06A77E
Record Status Validated (UNII)
Record Version